On January 10, 2025, Rein Therapeutics, Inc., formerly known as Aileron Therapeutics (NASDAQ:RNTX), Inc., announced amendments to its corporate charter to reflect a change in the company's name. The change became effective at 4:00 p.m. Eastern Time on the same day, as filed with the Secretary of State of Delaware.
The company's Board of Directors approved the name change in accordance with Section 242 of the General Corporation Law of the State of Delaware. This rebranding does not alter the rights of the company's stockholders and is accompanied by no other changes to the Certificate of Incorporation.
Concurrently with the name change, the company's Amended and Restated Bylaws were also amended to reflect the new corporate name. These documents are filed as exhibits with the Securities and Exchange Commission and incorporated by reference.
Following the rebranding, Rein Therapeutics' common stock will trade on The Nasdaq Capital Market under a new ticker symbol, "RNTX", starting from January 13, 2025. Despite the change in the trading symbol, the CUSIP number for the company's common stock remains unchanged.
The information reported is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.